• Mon, May 6, 2024
Matt Miksic Maintained (TNDM) at Buy with Increased Target to $55 on, May 6th, 2024
Matt Miksic of Barclays, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Buy with Increased Target from $39 to $55 on, May 6th, 2024.
Matt has made no other calls on TNDM in the last 4 months.
There are 7 other peers that have a rating on TNDM. Out of the 7 peers that are also analyzing TNDM, 3 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jeff Johnson of "Baird" Maintained at Hold with Increased Target to $36 on, Friday, May 3rd, 2024
- Joanne Wuensch of "Citigroup" Maintained at Hold with Increased Target to $38 on, Wednesday, April 3rd, 2024
- Rick Wise of "Stifel" Maintained at Hold with Increased Target to $24 on, Monday, February 5th, 2024
These are the ratings of the 4 analyists that currently disagree with Matt
- Larry Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $50 on, Friday, May 3rd, 2024
- Mathew Blackman of "Stifel" Maintained at Strong Buy with Increased Target to $45 on, Friday, May 3rd, 2024
- Matt O'Brien of "Piper Sandler" Reiterated at Buy with Increased Target to $50 on, Friday, May 3rd, 2024
- Mike Kratky of "Leerink Partners" Upgraded from Hold to Buy and Increased Target to $45 on, Thursday, April 25th, 2024